<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00128518</url>
  </required_header>
  <id_info>
    <org_study_id>2003.340</org_study_id>
    <nct_id>NCT00128518</nct_id>
  </id_info>
  <brief_title>IDEAL Study: Identification of the Determinants of the Efficacy of Arterial Blood Pressure Lowering Drugs</brief_title>
  <official_title>IDEAL Study : Identification of the Determinants of the Efficacy of Arterial Blood Pressure Lowering Drugs</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <brief_summary>
    <textblock>
      The principal scientific objective of the trial is to identify the factors that are
      associated with differential blood pressure responses between drugs. This may allow
      investigators to produce new hypotheses on the pathophysiology of hypertension and on the
      mechanisms of drug action.

      These factors can be of different types:

        -  Environmental factors (sodium or alcohol intake);

        -  Morphological (height, weight, body mass index, body surface area);

        -  Initial blood pressure;

        -  Electrocardiogram (ECG) parameters of left ventricular hypertrophy;

        -  Biological parameters as the activity level of the renin angiotensin aldosterone system;

        -  Genetic polymorphisms.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2004</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood pressure at the end of each 4 week treatment period</measure>
    <time_frame>16 weeks</time_frame>
    <description>Change from baseline and after each 4 week treatment period</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">139</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Group A : T1+P2 ● P1+P2 ● T2+P1 ● P1+P2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>T1 = perindopril T2 = Indapamide P1 = Placebo of T1 P2 = Placebo of T2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B : P1+P2 ● T1+P2 ● P1+P2 ● T2+P1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>T1 = perindopril T2 = Indapamide P1 = Placebo of T1 P2 = Placebo of T2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C : T2+P1 ● P1+P2 ● T1+P2 ● P1+P2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>T1 = perindopril T2 = Indapamide P1 = Placebo of T1 P2 = Placebo of T2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group D : P1+P2 ● T2+P1 ● P1+P2 ● T1+P2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>T1 = perindopril T2 = Indapamide P1 = Placebo of T1 P2 = Placebo of T2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Indapamide (T2)</intervention_name>
    <description>1.5 mg/day during 4 weeks</description>
    <arm_group_label>Group A : T1+P2 ● P1+P2 ● T2+P1 ● P1+P2</arm_group_label>
    <arm_group_label>Group B : P1+P2 ● T1+P2 ● P1+P2 ● T2+P1</arm_group_label>
    <arm_group_label>Group C : T2+P1 ● P1+P2 ● T1+P2 ● P1+P2</arm_group_label>
    <arm_group_label>Group D : P1+P2 ● T2+P1 ● P1+P2 ● T1+P2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Perindopril (T1)</intervention_name>
    <description>4 mg/day during 1 week then 8 mg/day during 3 weeks</description>
    <arm_group_label>Group A : T1+P2 ● P1+P2 ● T2+P1 ● P1+P2</arm_group_label>
    <arm_group_label>Group B : P1+P2 ● T1+P2 ● P1+P2 ● T2+P1</arm_group_label>
    <arm_group_label>Group C : T2+P1 ● P1+P2 ● T1+P2 ● P1+P2</arm_group_label>
    <arm_group_label>Group D : P1+P2 ● T2+P1 ● P1+P2 ● T1+P2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo of Perindopril (P1)</intervention_name>
    <description>1 pill/day during 1 week then 2 pills/day during 3 weeks</description>
    <arm_group_label>Group A : T1+P2 ● P1+P2 ● T2+P1 ● P1+P2</arm_group_label>
    <arm_group_label>Group B : P1+P2 ● T1+P2 ● P1+P2 ● T2+P1</arm_group_label>
    <arm_group_label>Group C : T2+P1 ● P1+P2 ● T1+P2 ● P1+P2</arm_group_label>
    <arm_group_label>Group D : P1+P2 ● T2+P1 ● P1+P2 ● T1+P2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo of Indapamide (P2)</intervention_name>
    <description>1 pill/day during 4 weeks</description>
    <arm_group_label>Group A : T1+P2 ● P1+P2 ● T2+P1 ● P1+P2</arm_group_label>
    <arm_group_label>Group B : P1+P2 ● T1+P2 ● P1+P2 ● T2+P1</arm_group_label>
    <arm_group_label>Group C : T2+P1 ● P1+P2 ● T1+P2 ● P1+P2</arm_group_label>
    <arm_group_label>Group D : P1+P2 ● T2+P1 ● P1+P2 ● T1+P2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants have to be 25 to 60 years of age

          -  Both genders

          -  Systolic blood pressure of 140 mmHg or above; diastolic blood pressure of 90 mmHg or
             above.

          -  Cardiovascular risk must not be high, to allow for two periods of 4 weeks of placebo
             without ethical concern.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francois GUEYFFIER, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospices Civils de Lyon</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital Louis Pradel</name>
      <address>
        <city>BRon</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 9, 2005</study_first_submitted>
  <study_first_submitted_qc>August 9, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 10, 2005</study_first_posted>
  <last_update_submitted>December 29, 2011</last_update_submitted>
  <last_update_submitted_qc>December 29, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 2, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hypertension - Drugs - Blood pressure response - Responders - pharmacogenetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Perindopril</mesh_term>
    <mesh_term>Indapamide</mesh_term>
    <mesh_term>Antihypertensive Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

